FISH 14q32.3 IGH Gene Breakapart Test
Comprehensive Genetic Analysis for Hematological Malignancies
The FISH 14q32.3 IGH Gene Breakapart Test represents a cutting-edge molecular diagnostic approach for detecting specific genetic abnormalities in hematological cancers. This sophisticated cytogenetic analysis focuses on the immunoglobulin heavy chain (IGH) gene located at chromosome 14q32.3, a critical region frequently involved in various B-cell malignancies. Using advanced fluorescence in situ hybridization (FISH) technology, this test provides unparalleled precision in identifying gene rearrangements that drive cancer development and progression.
What Does the Test Measure and Detect?
The FISH 14q32.3 IGH Gene Breakapart Test specifically targets and analyzes:
- IGH Gene Rearrangements: Detects breakpoints within the immunoglobulin heavy chain gene
- Chromosomal Translocations: Identifies specific translocations involving chromosome 14q32.3
- Genetic Abnormalities: Uncovers molecular changes associated with B-cell lymphomas and leukemias
- Disease-Specific Markers: Provides critical diagnostic information for various hematological malignancies
Who Should Consider This Test?
This specialized genetic test is recommended for patients presenting with:
- Suspected or diagnosed B-cell lymphomas
- Unexplained lymphadenopathy or organomegaly
- Abnormal blood cell counts suggestive of hematological disorders
- Patients requiring precise diagnosis and classification of leukemia subtypes
- Individuals needing prognostic assessment for treatment planning
- Cases where conventional cytogenetic analysis yields normal results despite clinical suspicion
Clinical Benefits of IGH Gene Breakapart Testing
Undergoing the FISH 14q32.3 IGH Gene Breakapart Test provides numerous clinical advantages:
- Accurate Diagnosis: Enables precise classification of hematological malignancies
- Prognostic Information: Helps predict disease course and treatment response
- Treatment Guidance: Informs targeted therapy selection and monitoring
- Minimal Residual Disease Detection: Assists in monitoring treatment effectiveness
- Comprehensive Risk Assessment: Provides valuable information for clinical decision-making
Understanding Your Test Results
Your FISH 14q32.3 IGH Gene Breakapart Test results will be interpreted by our expert cytogeneticists and hematologists:
- Normal Result: No IGH gene rearrangement detected, suggesting absence of specific genetic abnormalities
- Positive Result: Indicates presence of IGH gene rearrangement, confirming specific hematological malignancy
- Quantitative Analysis: Provides percentage of cells showing abnormal genetic patterns
- Clinical Correlation: Results are interpreted in context of clinical presentation and other laboratory findings
Test Pricing and Availability
| Price Type | Amount (USD) |
|---|---|
| Discount Price | $150 |
| Regular Price | $212 |
Nationwide Testing Availability
We proudly offer comprehensive genetic testing services across the United States, with convenient locations in major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our state-of-the-art laboratories ensure consistent, high-quality results regardless of your location.
Sample Requirements and Processing
Turnaround Time: Samples accepted daily by 4 pm; Reports available in 4 days
Sample Type: 5 mL (3 mL minimum) whole blood OR 4 mL (2 mL minimum) Bone Marrow from 2 Green Top (Sodium Heparin) tubes
Shipping Instructions: Ship at 18-22°C. DO NOT FREEZE
Required Documentation: Duly filled Chromosome & FISH analysis Requisition Form (Form 17) is mandatory
Take Control of Your Health Today
Don’t wait to get the critical genetic information you need for accurate diagnosis and effective treatment planning. Our team of experienced oncologists, hematologists, and cytogenetic specialists are ready to provide you with comprehensive care and support throughout your testing journey.
Call or WhatsApp us today at +1(267) 388-9828 to schedule your FISH 14q32.3 IGH Gene Breakapart Test and take the first step toward personalized, targeted cancer care.
